Trial Profile
An expanded access trial of Cabozantinib
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 09 Jan 2019
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 15 Oct 2018 New trial record
- 08 Oct 2018 According to an Exelixis media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress.